Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

RELEASE DATE
04-Sep-2018
REGION
North America
Research Code: ME1D-01-00-00-00
SKU: HC03076-NA-MR_22287

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC03076-NA-MR_22287

$3,000.00

$2,250.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google—pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.

Research Scope

The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies.

Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce, and so on.

The participants mentioned in the study are iSolve, Zephyr Health, PillPack, Proteus Digital Health, BenevolentAI, Elemental Machines, Exscientia, Science 37, Transparency Life Sciences, and uMotif. It also lists the wider universe of companies that were assessed for this analysis. These companies were chosen based factors such as innovative technology development and application, hitting the right focus areas, proven success and industry recognition, and enhanced client collaborations.


Key Issues Addressed

  • How are companies creating extraordinary value for pharmaceutical stakeholders?
  • Which are some unique companies that are introducing new and innovative solutions in the market?
  • How do these companies intend to transform the healthcare industry paradigms in the future? What is the impact of the external industry environment on this market?
  • What is their action plan and potential for growth? What are the current growth opportunities in digital transformation?
  • What are some key success factors in the pharmaceutical market?
  • Which are the companies with whom partnerships can be forged?

 

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings

Methodology

Scope and Segmentation

Key Questions this Study will Answer

Pillars of Digital Transformation and Growth Opportunity in Pharmaceuticals

Tackling Challenges in the Pharmaceuticals Industry

Major Challenges Limiting Digital Transformation

Companies-to-Action Value Creators

Threats and Opportunities

Strategic Imperatives for Digital Transformation in Pharmaceuticals

Definition and Solution Segmentation

Impact of Key Market Influencers

Pillars of Digital Transformation and Vendor Strategies

C2A Targets Aligned With Pillars of Digital Transformation

Value Chain Analysis

Benchmarking of Top Companies-to-Action

BenevolentAI

BenevolentAI (continued)

Exscientia

Exscientia (continued)

Science 37

Science 37 (continued)

Transparency Life Science

Transparency Life Sciences (continued)

Elemental Machines

Elemental Machines (continued)

iSolve

iSolve (continued)

PillPack

PillPack (continued)

Zephyr Health

Zephyr Health (continued)

Proteus Digital Health

Proteus Digital Health (continued)

uMotif

uMotif (continued)

Building Life Science Digital Capabilities by Innovation Tracking

Conclusion—Key Takeaways From the Companies-to-Action Analysis

Legal Disclaimer

List of Vendors Assessed

List of Vendors Assessed (continued)

List of Vendors Assessed (continued)

List of Vendors Assessed (continued)

List of Vendors Assessed (continued)

List of Vendors Assessed (continued)

List of Vendors Assessed (continued)

List of Vendors Assessed (continued)

List of Exhibits

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google—pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.--BEGIN PROMO--

Research Scope

The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies.

Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce,

More Information
No Index No
Podcast No
Author Neelotpal Goswami
Industries Healthcare
WIP Number ME1D-01-00-00-00
Is Prebook No
GPS Codes 9562-B1,9564-B1,9568-B1,9571-B1,9573-B1,9575-B1,9600-B1,9611-B1,9612-B1,9627-B1,99BC-B1,99C1-B1,99C6-B1,9A42-B1,9A43-B1,9A44-B1,9A4E-B1